Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

erfonrilimab (KN046)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Alphamab

Drug class:

PD-L1 inhibitor, CTLA4 inhibitor

Related drugs:

‹

atezolizumab (236)

durvalumab (199)

sugemalimab (7)

envafolimab (6)

IO102-IO103 (4)

socazolimab (2)

atezolizumab and hyaluronidase-tqjs (1)

adebrelimab (0)

CF33-hNIS-antiPDL1 (0)

PD-L1.t-haNK (0)

PF-07257876 (0)

Undisclosed anti-PD-L1 antibody (0)

ipilimumab (223)

tremelimumab (60)

cadonilimab (10)

iparomlimab/tuvonralimab (3)

ipilimumab biosimilar (CS1002) (2)

CTLA4 inhibitor (0)

IBI310 (ipilimumab biosimilar) (0)

prolgolimab/nurulimab (0)

PF-06753512 (0)

›

HER-2 amplification	Solid Tumor	HER-2 amplification	Solid Tumor	KN046 + KN026 Sensitive: C2 – Inclusion Criteria KN046 + KN026 Sensitive : C2	KN046 + KN026 Sensitive: C2 – Inclusion Criteria KN046 + KN026 Sensitive : C2
HER-2 positive	Solid Tumor	HER-2 positive	Solid Tumor	KN046 + KN026 Sensitive: C2 – Inclusion Criteria KN046 + KN026 Sensitive : C2	KN046 + KN026 Sensitive: C2 – Inclusion Criteria KN046 + KN026 Sensitive : C2
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	KN046 + KN026 Sensitive: C2 – Inclusion Criteria KN046 + KN026 Sensitive : C2	KN046 + KN026 Sensitive: C2 – Inclusion Criteria KN046 + KN026 Sensitive : C2
HER-2 positive	Gastrointestinal Cancer	HER-2 positive	Gastrointestinal Cancer	KN046 + KN026 Sensitive: C2 – Inclusion Criteria KN046 + KN026 Sensitive : C2	KN046 + KN026 Sensitive: C2 – Inclusion Criteria KN046 + KN026 Sensitive : C2
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	KN046 + KN026 Sensitive: C2 – Inclusion Criteria KN046 + KN026 Sensitive : C2	KN046 + KN026 Sensitive: C2 – Inclusion Criteria KN046 + KN026 Sensitive : C2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	KN046 + KN026 Sensitive: C2 – Inclusion Criteria KN046 + KN026 Sensitive : C2	KN046 + KN026 Sensitive: C2 – Inclusion Criteria KN046 + KN026 Sensitive : C2
HER-2 underexpression	Solid Tumor	HER-2 underexpression	Solid Tumor	KN046 + KN026 Sensitive: C3 – Early Trials KN046 + KN026 Sensitive : C3	KN046 + KN026 Sensitive: C3 – Early Trials KN046 + KN026 Sensitive : C3
HER-2 mutation	Solid Tumor	HER-2 mutation	Solid Tumor	KN046 + KN026 Sensitive: C3 – Early Trials KN046 + KN026 Sensitive : C3	KN046 + KN026 Sensitive: C3 – Early Trials KN046 + KN026 Sensitive : C3
HER-2 overexpression	Solid Tumor	HER-2 overexpression	Solid Tumor	KN046 + KN026 Sensitive: C3 – Early Trials KN046 + KN026 Sensitive : C3	KN046 + KN026 Sensitive: C3 – Early Trials KN046 + KN026 Sensitive : C3
PD-L1 expression	Triple Negative Breast Cancer	PD-L1 expression	Triple Negative Breast Cancer	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3
RET fusion	Non Small Cell Lung Cancer	RET fusion	Non Small Cell Lung Cancer	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3
EGFR amplification	Non Small Cell Lung Cancer	EGFR amplification	Non Small Cell Lung Cancer	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3
PD-L1 expression	Thymic Carcinoma	PD-L1 expression	Thymic Carcinoma	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3